Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicentre, Open-label, Dose-escalating Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS)

NCT00464321 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT00464321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00464321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicentre, Open-label, Dose-escalating Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2007
Completion date
February 28, 2010
Enrollment
16 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis